Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Total Liabilities (2016 - 2025)

Vanda Pharmaceuticals' Total Liabilities history spans 17 years, with the latest figure at $161.8 million for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 37.48% to $161.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $161.8 million, a 37.48% increase, with the full-year FY2025 number at $161.8 million, up 37.48% from a year prior.
  • Total Liabilities hit $161.8 million in Q4 2025 for Vanda Pharmaceuticals, up from $135.1 million in the prior quarter.
  • Over the last five years, Total Liabilities for VNDA hit a ceiling of $161.8 million in Q4 2025 and a floor of $75.6 million in Q1 2021.
  • Historically, Total Liabilities has averaged $108.0 million across 5 years, with a median of $105.0 million in 2022.
  • Biggest five-year swings in Total Liabilities: fell 7.19% in 2023 and later skyrocketed 37.48% in 2025.
  • Tracing VNDA's Total Liabilities over 5 years: stood at $88.9 million in 2021, then grew by 20.46% to $107.0 million in 2022, then fell by 3.29% to $103.5 million in 2023, then rose by 13.65% to $117.7 million in 2024, then surged by 37.48% to $161.8 million in 2025.
  • Business Quant data shows Total Liabilities for VNDA at $161.8 million in Q4 2025, $135.1 million in Q3 2025, and $138.4 million in Q2 2025.